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ImmunogenicityThe generation of effective immune responses by mucosal vaccination without the use of inﬂammatory ad-
juvants, that compromise the epithelial barrier and recruit new cellular targets, is a key goal of vaccines
designed to protect against sexually acquired pathogens. In the present study we use a model HIV antigen
(CN54gp140) conjugated to transferrin (Tf) and evaluate the ability of the natural transferrin receptor
CD71 to modulate immunity. We show that the conjugated transferrin retained high afﬁnity for its receptor
and that the conjugate was speciﬁcally transported across an epithelial barrier, co-localizing with MHC Class
II+ cells in the sub-mucosal stroma. Vaccination studies in mice revealed that the Tf-gp140 conjugate elicited
high titres of CN54gp140-speciﬁc serum antibodies, equivalent to a systemic vaccination, when conjugate
was applied topically to the nasal mucosae whereas gp140 alone was poorly immunogenic. Moreover, the
Tf-gp140 conjugate elicited both IgG and IgA responses and signiﬁcantly higher gp140-speciﬁc IgA titre in
the female genital tract than unconjugated antigen. These responses were achieved after mucosal application
of the conjugated protein alone, in the absence of any pro-inﬂammatory adjuvant and suggest a potentially
useful and novel molecular targeting approach, delivering a vaccine cargo to directly elicit or enhance
pathogen-speciﬁc mucosal immunity.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Mucosal epithelia and associated lymphoid tissues are the primary
route of entry for a large number of infectious pathogens, including sex-
ually transmitted infections that have a high and increasing incidence.
Effective vaccination strategies should establish immunity at these por-
tals of entry, the exposedmucosa and local draining lymph nodes. Anti-
bodies present at mucosal surfaces have the potential to completely
prevent overt infection by enhancing the protection provided by the
mucosal physical barrier, but to stimulate such a response it is likely
that vaccination modalities will require a mucosal component that can
enlist and direct responses to “home” to mucosal tissue, while main-
taining the integrity of the barrier mucosae. Most vaccination regimes,
however, use potent adjuvants that enhance the apparent “danger” ofniversity of London by the Bill
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rights reserved.a vaccine antigen, by stimulation of several families of pattern recogni-
tion receptors (PRRs) and/or direct recruitment of immune responsive
cells, leading to local inﬂammation and disruption of mucosal epithelial
integrity [1,2]. The mucosa is a highly structured, complex tissue with
distinct areas that have dense aggregations of T, B, dendritic cells and
macrophages as well as areas virtually devoid of immune cells [3]. The
immune cells can be either normally resident or transient sentinels
that survey mucosal tissue for incoming antigen or danger signals and
all cells within the mucosae, including epithelial and stromal cells, ex-
hibit a high degree of cross-talk, two-way interactions that can often
have signiﬁcant down-stream functional effects upon the elicitation of
immune responses to a vaccine antigen [4–6]. The cell type within the
sub-mucosae and mucosal lamina propria likely to be central to elicita-
tion of bothmucosal and systemic immune responses is the profession-
al antigen-presenting dendritic cell and we set out to deliver antigen to
these target cells [3,6]. We hypothesized that increasing the amount of
vaccine antigen transported across the epithelial barrier will augment
dendritic cell elicited immune responses and utilized the natural trans-
cytotic capacity of the transferrin receptor CD71 to achieve this goal.
Our overall aim was to generate immune responses within the
vaginal mucosae and it has previously been shown that the female
genital tract has some immune inductive potential. For example,
intravaginal vaccination studies utilizing Toll-like receptor (TLR) ago-
nists and CD4+ T helper epitopes [7] or powerful adjuvants such as
241J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249cholera toxin [8] have demonstrated that immunization at this muco-
sal surface is possible but responses elicited to unadjuvanted vaccine
antigens, where vaginal epithelial barrier integrity is maintained,
have beenmodest [9,10]. This may be due to a number of reasons, dis-
tinct from the recruitment and activation of immune responsive cells,
such as the inability of vaccinating antigens to traverse the type II
stratiﬁed squamous epithelial barrier characteristic of the lower fe-
male reproductive tract [11], the possibility that the female reproduc-
tive tract is directed more towards an induced state of tolerance
rather than inﬂammation [12], vaginal leakage of the applied antigen
[13] or sequestration and elimination of the antigen by locally pro-
duced mucus and proteases [14,15]. For human immunodeﬁciency
virus (HIV) there is the additional concern that vaccine/adjuvant-in-
duced local inﬂammation may fuel infection through the recruitment
of target cells as suggested by a recent clinical trial. The MRKAd5 HIV-
1 gag/pol/nef vaccine appeared to result in a higher HIV-1 incidence
in the vaccine-treated cohort than the placebo-treated cohort, partic-
ularly amongst uncircumcised men who had a pre-existing Ad5 im-
munity, and who may have experienced higher local inﬂammation
than control subjects [16]. Therefore, the challenge facing any vaginal
mucosal vaccine is how to overcome these potential pitfalls.
We have therefore focused on an intranasal mucosal vaccine deliv-
ery system with low inﬂammatory potential that is capable of deliver-
ing an immunizing cargo and eliciting systemic and intravaginal
immune responses. We have investigated a molecular targeting based
approach to deliver a model vaccine cargo to mucosal tissues with the
aim of increasing vaccine antigen bio-availability within the mucosal
lamina propria and enhancing immune responses elicited by cells resi-
dent or transiently present in mucosal compartments. We used trans-
ferrin as the targeting component conjugated to a trimeric HIV gp140
model vaccine antigen cargo via biotin–streptavidin linkage (Tf-
gp140). Transferrin targets the highly efﬁcient transcytotic and recy-
cling transferrin receptor (CD71) that is expressed on both nasal and
vaginal mucosal epithelium, is actively transcytosed and has been suc-
cessfully utilized as a delivery system for drug conjugates, when associ-
ated with microparticles or emulsion formulations, for the delivery of
anti-cancer agents and in gene therapy [17]. Importantly, transferrin
has been utilized as a trans-mucosal delivery modality for oral insulin
preparations in a rat model of diabetes, suggesting that the CD71-
transferrin transcytotic route has a realistic potential as an effectivemu-
cosal vaccine delivery strategy [18]. We sought to stringently test this
hypothesis through linkage of transferrin to a large, stable trimeric
Clade C HIV gp140 model antigen that was topically applied to mucosal
epithelium that expressed apical to basolateral cycling CD71molecules.
We report here the ability to generate systemic and vaginal antibody
responses after nasal but not vaginal immunization in the absence of an
adjuvant. Nasal mucosal immunization alone with the Tf-gp140 conju-
gate elicited comparable serum and mucosal titres to those obtained
after prior subcutaneous priming followed by nasal mucosal boosting
with unconjugated gp140. Interestingly however, nasal immunization
alone with Tf-gp140 induced a striking IgG1 (Th2) biased serum re-
sponse and a signiﬁcant augmentation in anti-gp140 mucosal IgA re-
sponse in cervico-vaginal ﬂuid. Thus, a mucosally-applied and
receptor-targeted approach can generate high titre antibody-speciﬁc
responses to a large vaccine antigen conjugate in both the systemic
andmucosal compartments highlighting the utility of Tf-gp140 as an ef-
fective means to generate vaginal antigen-speciﬁc antibody responses
while unconjugated gp140 alone was ineffective.
2. Materials and methods
2.1. Recombinant trimeric HIV-1 gp140
A clade C HIV-1 envelope clone, designated p97CN54, was
obtained from an HIV infected Chinese patient [19,20] and made
available by Prof. H. Wolf and Prof. R. Wagner (University ofRegensburg, Germany). Trimeric gp140 clade C envelope (gp120
plus the external domain (ED) of gp41), designated CN54gp140,
was produced as a recombinant product in CHO cells (S. Jeffs—per-
sonal communication), and the protein manufactured to GMP speciﬁ-
cation by Polymun Scientiﬁc (Vienna, Austria). The ﬁdelity of the
product was conﬁrmed by mass spectrometric analysis of tryptic frag-
ments by the Medical Biomics Centre at St. George's, University of
London. The trimeric product was stable, even when kept at room
temperature (D. Katinger—personal communication) and has previ-
ously been reported to be immunogenic [21,22].
2.2. Transferrin-gp140 chemical conjugation
gp140 antigen was reacted with streptavidin in a 1:1 molar ratio
using a Lightning-Link™ conjugation kit (Innova Biosciences, UK).
Brieﬂy, CN54gp140 was modiﬁed using the LL-modiﬁer and mixed
gently. Modiﬁed CN54gp140 was then added to the streptavidin and
the reaction was incubated at room temperature for 3 hours before
the reaction was stopped using the LL-quench. The modiﬁed protein
was incubated for a further 30 min to ensure that the reaction had
terminated. A relevant volume of biotinylated transferrin (Sigma,
UK) at 5 mg/ml was then added to the gp140 streptavidin and the re-
action was incubated for 1 hour.
2.3. Malvern zeta sizer analysis of conjugate
Conjugate size and particle distribution were measured using dy-
namic light scattering with a Malvern Zeta-Sizer (Malvern Instru-
ments Ltd., UK) at 25 °C. Brieﬂy, 10 μg protein was diluted into
300 μl PBS and placed into an analysis cuvette (Sigma-Aldrich Ltd.,
UK). The intensity of laser light scattered by the sample preparations
was measured at 173° to the incident beam. The data were analyzed
using proprietary Malvern software, DTS (Nano Version 5.0), supplied
with the machine. The size distribution and the polydispersity were
measured using non-invasive back scatter (NIBS).
2.4. Receptor–ligand binding afﬁnity
The binding properties of the Tf-gp140 conjugate to transferrin re-
ceptor (CD71) were assessed using a Rapid 4 acoustic biosensor (TTP
LabTech, UK). CD71 (Europa Bioproducts Ltd., UK) was immobilized
on a quartz crystal chip (AccuBio, UK), and then either apo-
transferrin, holo-transferrin or the Tf-gp140 conjugate was allowed
to ﬂow over the bound ligand. The binding of the different forms of
transferrin or transferrin conjugate to the chip-bound CD71 effects a
change in bound mass, which is detected as a difference in resonant
frequency of the quartz cassette, allowing the determination of the
binding kinetics between the transferrin alone or Tf-gp140 conjugate
and the CD71, according to the Langmuir model.
2.5. Primary endocervical epithelium isolation, ﬂow cytometric analysis
and in vitro transwell studies
Cervical mucosal tissue was collected from pre-menopausal
women undergoing therapeutic hysterectomies at St. George's, and
Kingston Hospitals (London, United Kingdom); the tissue was dis-
sected, digested with dispase II and primary endocervical cultures
were established. These cells were analyzed by ﬂow cytometry and
used in transwell experiments (supplementary methods).
2.6. Mice, immunization and sampling
Female BALB/c mice (Harlan, UK), 6–8 weeks old, were placed into
groups (n=8) and housed in a fully acclimatized room. All animals
were handled and procedures were performed in accordance with
the UK Home Ofﬁce Animals (Scientiﬁc Procedures) Act 1986. One
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thereafter, mice receiving vaginal immunizations were treated with
2 mg of medroxy-progesterone (Pharmacia, UK) administered subcu-
taneously to synchronize the menstrual cycle and thin the vaginal ep-
ithelium. Food and water were supplied ad libitum.
Mice were immunized at 2 weekly intervals with three intravagi-
nal or intranasal mucosal applications of 50 μg gp140 or Tf-gp140
conjugate. Alternatively, the mice were exposed to the gp140 antigen
before mucosal vaccination by a single subcutaneous injection of
10 μg gp140 followed by the three, two weekly interval, 50 μg intra-
vaginal or intranasal immunizations with gp140 or Tf-gp140. A con-
trol group received a single subcutaneous injection of 10 μg gp140.
Tail bleeds were collected weekly without anti-coagulant and centri-
fuged in a Heraeus Biofuge Pico (Fisher, UK) at 1000g for 10 min. The
serum was harvested and transferred into fresh 0.5 ml micro-
centrifuge tubes (Starlabs, UK), and stored at −20 °C until antibody
titres were determined by indirect ELISA. Vaginal lavage was carried
out weekly using three 25 μl washes/mouse with PBS that were sub-
sequently pooled. Lavage samples were incubated for 30 min with
4 μl of 25× stock solution protease inhibitor (Roche Diagnostics, Ger-
many) before centrifuging at 1000g for 10 min. The ﬂuid supernatant
from these treated samples was then transferred into a fresh 0.5 ml
micro-centrifuge tube, and stored at −20 °C until antibody titres
were determined by indirect ELISA.b
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)2.7. In vivo ﬂuorescence
Real time bio-imaging of topically applied ﬂuorescently-labeled
transferrin was performed using a multispectral Carestream In Vivo
FX Pro system (USA). Brieﬂy, a 100 μg dose of Tf-Alexa 647 nm was
applied in a 15 μl volume to the vaginal or nasal mucosa of anesthe-
tized female BALB/c mice. Imaging was carried out immediately
after application of Tf-Alexa and at various time points dependent
on the tissue of interest. Photonic emissions were captured after a
15 second exposure with a 670 nm ﬁlter and images were acquired
and analyzed using Carestream software (USA).c
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Samples from primary cell cultures or immunized mice were var-
iously analyzed using an anti-human transferrin, a CN54gp140
antigen-speciﬁc and an anti-CN54 antibody ELISA. Full details of the
ELISA methods used are included in the supplementary method
section.60
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Fig. 1. Formation, physical and functional analysis of Tf-gp140 conjugate. a) Tris-acetate gel
electrophoresis of gp140, streptavidinated gp140, transferrin, biotinylated transferrin and
the conjugate formed by combination of the streptavidin- and biotin-labeled components.
Optimal conjugate formed at a ratio of 4:1 biotinylated transferrin:gp140-streptavidin2.9. Immunohistochemistry
To visualize the ability of transferrin or the Tf-gp140 conjugate to
translocate into the submucosal environment from an external lumi-
nal compartment, vaginal or nasal tissue was removed from treated
animals, and then embedded in OCT Cryomatrix (RA Lamb, USA)
and ﬂash frozen in liquid nitrogen. Endocervical tissue from patients
undergoing planned therapeutic hysterectomy (local Research Ethics
Committee approval was obtained) were cut into 3 mm3 samples and
placed into 10% formaldehyde overnight at 4 °C. Tissue samples were
loaded into histocasettes (Fisher, UK) and parafﬁn embedded over-
night. Sections were cut from these prepared tissues and stained as
described in the supplementary methods section.(Tf-gp140; Lane 8). b) Size distribution curves normalized for % volume for transferrin
( ), gp140 ( ) and the Tf-gp140 conjugate ( ) obtained by dynamic light scattering
at 25 °C using a Malvern Zeta-sizer. The intensity of the laser light scattered by the sample
preparationswas detected at 173° to the incident beam. Data were analyzed usingMalvern
DTS (Nano Version 5.0) software. c) Apo-transferrin ( ), holo-transferrin ( ) and
Tf-gp140 conjugate ( ) binding and dissociating with immobilized transferrin receptor
(CD71) were assessed using an acoustic biosensor.2.10. Statistical analysis
Statistical analysis of the datawas carried out by theMann–Whitney
rank-sum test using Prism (GraphPad Software, Inc., USA).3. Results
3.1. Transferrin-CN54gp140 conjugate and native transferrin have simi-
lar CD71 binding afﬁnities
To utilize the highly efﬁcient transcytotic capacity of the CD71
transferrin receptor, biotinylated transferrin was conjugated to strep-
tavidinated recombinant trimeric HIV CN54gp140. The addition of
243J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249streptavidin increased the apparent relative molecular mass of gp140
as did the addition of biotin to transferrin (Fig. 1a). We found that a
4:1 molar ratio of transferrin–biotin to CN54gp140-streptavidin was
necessary to combine all reactants efﬁciently. This resulted in a conju-
gate that just entered a 7–10% gel due to its large mass (Fig. 1a, Tf-Epithelium
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agp140). Zeta–Sizer analysis of this conjugate revealed that it had a
more poly-dispersed proﬁle than either component alone and con-
tained particle sizes ranging from 200 to 400 nm in diameter
(Fig. 1b) in addition to smaller species. Next, the ability of the conju-
gate to bind to the transferrin receptor, CD71, was determined by res-
onant acoustic proﬁling (Fig. 1c). The CD71 molecule was covalently
bound to the sensor chip and the binding of the three different trans-
ferrin moieties (holo-transferrin, apo-transferrin or Tf-gp140) was
measured. The association and dissociation rates for transferrin or
the Tf-gp140 conjugate (normalized for transferrin concentration)
were used to calculate afﬁnity for chip-bound CD71. The multi-
molecular Tf-gp140 conjugate complex retained speciﬁc afﬁnity for
CD71 that was approximately 2-fold greater than transferrin alone,
with a 4.45×10−8 M afﬁnity of Tf-gp140 and a 1.02×10−7 M afﬁnity
of transferrin for the immobilized CD71 (Fig. 1c). Apo-transferrin
showed no speciﬁc binding to the CD71 molecule.3.2. The Tf-gp140 conjugate is actively and efﬁciently transcytosed across
human mucosal primary columnar epithelium in vitro
Conﬂuent monolayers of primary columnar epithelial cells derived
from human endocervical tissue cultured directly ex vivo were used
to assess the ability of transferrin to transport a bound cargo. The ex-
pression of CD71 on endocervical and murine intranasal surface epi-
thelia was conﬁrmed by immunohistochemistry (Fig. 2a and c).
Surface CD71 expression was further analyzed by ﬂow cytometry on
the primary cultured epithelial cells immediately prior to use in the
transwell system and showed that CD71 expression was retained
after isolation and short-term culture (Fig. 2b).
The ability of transferrin to speciﬁcally mediate the transport of
conjugated gp140 across the epithelial layer was evaluated. Tf-
gp140 or unconjugated gp140 was placed into the apical chamber
of the transwell system, in the presence or absence of the protein
transport inhibitor monensin, having conﬁrmed the formation of
intercellular tight junctions by resistance across the well. After
24 hours the Tf-gp140 transversed the conﬂuent epithelium 29.3
times more efﬁciently than unconjugated gp140 and this transport
was abolished in the presence of monensin (Fig. 2d). Next, human
transferrin was applied to the apical chamber of a transwell system
containing a conﬂuent layer of primary human endocervical epithelial
cells. Transferrin was detected in the basolateral chamber within
30 min and continued to accumulate, demonstrating a time-
dependent transport (Fig. 2e). This transport was, as expected, also
arrested using the intracellular protein transport inhibitor monensin
indicating that the transport was an active process (Fig. 2e). Active
transport of transferrin across the primary epithelia also occurred at
low transferrin concentrations (Fig. 2f). Importantly, conﬂuency and
high resistance were maintained throughout the course of the
experiments.Fig. 2. Human transferrin transcytosis is an active process that can transport an at-
tached vaccine antigen. a) Expression of CD71 on human endocervical columnar epi-
thelium. Sections were stained for human CD71 (right panel) or an isotype control
(left panel). b) Primary epithelial cells isolated from endocervical tissue were surface
stained with isotype-matched control or CD71-speciﬁc ﬂuorochrome labeled anti-
bodies and expression analyzed by ﬂow cytometry. c) Expression of murine CD71 on
intranasal epithelium. d) Transferrin can efﬁciently transport a large vaccine antigen.
A speciﬁc ELISA quantiﬁed gp140 in the basal transwell chamber 24 hours after appli-
cation of either unconjugated gp140 (50 μg) or the Tf-gp140 (50 μg) conjugate to the
apical chamber. The resistance across the transwell chambers was maintained
throughout all experiments. e) Human transferrin can traverse an intact human prima-
ry cervical epithelium transwell system. Human transferrin (500 μl of 1 mg/ml) was
added to the apical chamber of a transwell culture dish containing conﬂuent human
cervical epithelial cells and transferrin concentrations in the basolateral chamber de-
termined using a human transferrin ELISA after 30, 60 and 240 min in the presence
(□) or absence (■) of monensin. f) This speciﬁc transferrin transport occurs even at
low apical chamber transferrin concentrations, samples removed form basal chamber
at 24 hours.
244 J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–2493.3. Transferrin or Tf-gp140 traverse intact mucosal epithelium in vivo
and co-localize with submucosal APCs
Having determined that human transferrin can cross primary
human cervical epithelium in vitro, we next sought to visualize and
then assess the ingress of transferrin using an in vivo model. We
ﬁrst examined the residence time of topically applied human trans-
ferrin within the murine nasal cavity or vaginal vault (Fig. 3a–b).
We noted from in vivo imaging analysis that ﬂuorescently labeled
human transferrin was detectable within the vaginal vault for up to
48 hours (Fig. 3a) while the same quantity and volume of ﬂuorescent
transferrin was only observed in the nasal cavity for up to 5 hours
(Fig. 3b).
We then determined if human transferrin was able to functionally
utilize the murine transferrin receptor. After application of transferrin
to the vaginal vault or nasal mucosae of mice, human transferrin was
detected by a human Tf-speciﬁc ELISA in serum as early as 6 hours
after application (Fig. 4a–b). The concentration of human transferrin
detected in the serum continued to increase for 48 hours after appli-
cation by either route, with transferrin applied nasally accessing the
murine circulatory system at a faster rate, resulting in higher levels
being detected by 24 hours.
We then sought to track the progress of transferrin through the
mucosal barrier and any initial interactions with immune cells in
the sub-mucosal stroma. Here, we topically placed 100 μg of
ﬂuorochrome-labeled human transferrin (Tf-Alexa) into the vaginalFig. 3. Kinetics of in vivo Tf-Alexa ﬂuorescence after topical administration to vaginal
and nasal mucosa. 100 μg Tf-Alexa in a 15 μl volume was applied topically into the
mouse nasal cavity or the vaginal vault. a) Fluorescent signal acquired with a 1 second
exposure through a 670 nm ﬁlter after vaginal application to the right-hand mouse in
each panel. Images were taken at various times and the signal captured immediately
after application and at 24 and 48 hours is shown. b) Signal acquired after topical ap-
plication into the nasal cavity. Images were taken immediately after application and
at 4 and 5 hours. No ﬂuorescence was seen after 5 hours in any of a number (n>3)
of nasal applications. Animals were maintained under anesthetic during imaging but
were fully awake and active between each image capture. Image sample times are
shown above each panel while the scale bar represents ﬂuorescence light intensity.or nasal lumens. After application tissues were extracted, processed
and snap frozen and 6–8 μm sections were prepared. Tf-Alexa ﬂuores-
cence was detected in epithelia lining the nostrils and nasal conchae
(Fig. 4c–d). Under higher magniﬁcation, Tf-Alexa had clearly tra-
versed the mucosal epithelia of the nasal passages and entered into
the lamina propria, thus breaching the mucosal barrier and gaining
access to areas well documented to have an abundance of immune in-
ductive cells (Fig. 4e). Large amounts of Tf-Alexa can be seen through-
out the epithelial layer with deﬁned punctate staining within the
tissue stroma. Examination of vaginal tissue, after topical application
of Tf-Alexa, also revealed numerous punctate Tf-Alexa bodies being
observed underneath the surface epithelium in the lamina propria in-
dicating sufﬁcient accumulation of the ﬂuorochrome within cells to
enable visualization (Fig. 4f). However, little Tf-Alexa could be
detected within or at the epithelial surface. By staining for MHC
class II in vaginal tissues of mice administered with Tf-Alexa, co-
localization of Tf-Alexa and APCs could be observed demonstrating
that the transferrin not only transverses the epithelial barrier, but
can also access areas where immune inductive cells reside (Fig. 4g).
To test proof of principle that Tf can carry a vaccine antigen through
a mucosal epithelial barrier in vivo we applied 100 μg of the Tf-
gp140 conjugate into the mouse vaginal vault, harvested the vagina
after 2 hours and examined sections for the presence of gp140 pro-
tein using the gp140-speciﬁc 5F3 antibody. Staining conﬁrmed that
gp140 protein had crossed the mucosal epithelium and was present
in the stromal lamina propria of the vaginal tissue, becoming concen-
trated in cells with a dendritic morphology (Fig. 4h). No gp140 pro-
tein was detectable in sections from mice that had received
unconjugated protein. Taken together these results indicate that the
capacity for transferrin to carry a vaccine cargo across an epithelial
layer was applicable in vivo as had been demonstrated in vitro.
3.4. Tf-gp140 elicits high-titre serum gp140-speciﬁc antibody responses
after intranasal but not intravaginal application
To determine the immunogenic potential of the Tf-gp140 conju-
gate mice were immunized mucosally at two-week intervals with ei-
ther 50 μg of gp140 or with 50 μg of Tf-gp140 conjugate, with or
without a subcutaneous priming with gp140. Primed groups received
a single subcutaneous injection of 10 μg of unadjuvanted gp140 pro-
tein 14 days before the ﬁrst mucosal inoculation (Day 0). Animals
that were vaccinated vaginally were pretreated with medroxyproges-
terone to thin the highly stratiﬁed murine vaginal epithelium. Appli-
cation of gp140, without adjuvants, to the nasal or vaginal vault
elicited only minimal immunity (Fig. 5a).
Following intranasal administration of the Tf-gp140 conjugate,
gp140-speciﬁc serum antibody responses were detected in 8 of
8 mice after a single application. Titres were strongly and signiﬁcantly
boosted with a second application, while the response to administra-
tion of gp140 alone was barely detectable (p=0.0002) (Fig. 5a). A
further intranasal vaccination did not increase titres in either group.
The antibody titres generated by two mucosal applications of the Tf-
gp140 conjugate were at least as high as levels achieved with prior
systemic priming with gp140 and two mucosal boosts with either
Tf-gp140 or the unconjugated gp140 antigen (p≥0.05). In contrast
to intranasal inoculation, application of Tf-gp140 to the vaginal muco-
sa did not elicit any serum gp140 antigen-speciﬁc responses,
highlighting the difference between the immune inductive potential
of these mucosal sites (Fig. 5a). However, in animals that were previ-
ously primed subcutaneously with gp140, serum antibody titres were
boosted signiﬁcantly by application of either gp140 (p=0.0002) or
Tf-gp140 (p=0.0019) via the vaginal route (Fig. 5b). Interestingly,
serum titres continued to rise after a third intravaginal vaccination
but failed to reach the level obtained by intranasal vaccination. Like-
wise, the antibody titres in animals subcutaneously primed with
unadjuvanted gp140 were boosted after nasal mucosal applications
245J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249of unconjugated gp140; however, high titres were attained in this in-
stance after only two mucosal immunizations (Fig. 5b). Crucially,
serum anti-gp140 titres obtained after nasal mucosal administration
of Tf-gp140 were not signiﬁcantly enhanced by prior subcutaneous
priming (p≥0.05). Analysis of the isotype sub-class composition of
the gp140 antigen-speciﬁc serum antibodies revealed that all animals
that responded showed an IgG1 isotype bias, likely due to the natural
Th2 skewing of BALB/c mice, but those animals that had been muco-
sally vaccinated with the Tf-gp140 conjugate exhibited a dramatic
further enhancement to the existing IgG1 isotype bias, indicating
that the Tf-gp140 conjugate may augment gp140-speciﬁc B cell dif-
ferentiation (Fig. 5c).3.5. Tf-gp140 elicits an IgA biased cervico-vaginal response following in-
tranasal application
Intravaginal administration of either gp140 or Tf-gp140 in the ab-
sence of subcutaneous priming, failed to stimulate a detectable IgG or
IgA response in cervico-vaginal lavage mirroring the lack of a serum
response (Fig. 6a, c). However, intranasal administration of either
gp140 or Tf-gp140 stimulated cervico-vaginal IgG antibody in 4 of
8 and 5 of 8 animals respectively with no statistical difference in the
mean titre (p≥0.05). Interestingly however, only 1 of 8 animals had
cervico-vaginal IgA antibody after nasal gp140 application whereas
8 of 8 animals had cervico-vaginal IgA after nasal administration of
Tf-gp140, with a statistically different GMT of 15.8 vs. 110.2
(p=0.0019) (Fig. 6a, c). As observed for serum responses, subcutane-
ous priming with gp140 facilitated efﬁcient nasal boosting with
gp140, all animals responding with IgG and IgA responses and no sta-
tistically signiﬁcant difference in GMT between gp140 or Tf-gp140
boosting (p≥0.05) (Fig. 6b, d). Although the mean titre of cervico-
vaginal IgA antibody was slightly higher if animals receiving nasal
Tf-gp140 were primed subcutaneously (110.2 vs. 274.8 (p≥0.05)),
at least for IgA it was evident that conjugation of transferrin to antigen
could overcome the absolute requirement for systemic immunization.
4. Discussion
Current thinking in vaccinology suggests that optimal generation
and maintenance of mucosal immunity may require inoculation at,
or within, mucosal tissues. However, vaccines comprised solely of
proteins that are not themselves toxins or ligands for pattern recogni-
tion receptors are typically poorly immunogenic when administered
systemically and are virtually immunologically invisible when ap-
plied topically to mucosal membranes [10,23,24]. Therefore to elicit
potent and long-lasting immunity, whether mucosal or systemic, it
is clear that the majority of potential protein vaccine antigens must
be adjuvanted or “immunologically assisted” by pro-inﬂammatory bi-
ological or biochemical agents. Such adjuvants will result in an in-
ﬂammatory response that can dramatically enhance a systemic
immunization and elicit vaccine-speciﬁc immunity without signiﬁ-
cant damage to the recipient and are already widely accepted and tol-
erated. However, the same vaccine adjuvant formulations applied
mucosally may cause damage to delicate epithelia and are likely to
be noticeably uncomfortable and therefore much less well tolerated.
This is highlighted by recent concerns that use of potent mucosal ad-
juvants with the capacity to bind gangliosides on the olfactory nerve
was associated with neurological side-effects, in particular unilateral
facial nerve paralysis, Bell's palsy [25,26]. In addition, it is the neces-
sarily high reactogenicity of these effective vaccine adjuvants at mu-
cosal surfaces that paradoxically may lead to a critical breach in the
most efﬁcient barrier to pathogen ingress—the mucosal epithelium.Fig. 4. Transferrin crosses mucosal epithelium in vivo, localizes to MHC Class II+ cells
and can transport a vaccine antigen to APC in the underlying stroma. a–b) Human
transferrin was quantiﬁed by speciﬁc ELISA in murine serum samples taken 6, 24 and
48 hours after application of human transferrin (20 μl of 1 mg/ml) into the vaginal
vault (a) or topically to the nasal mucosae (b). c) Tf-Alexa 647 applied intranasally in
mice was visualized in epithelium and within sub-epithelial stromal tissue (lamina
propria). Fluorescent signal is shown in phase contrast and with 4′-6-diamidino-2-
phenylindole (DAPI)-stained nuclei. d) Tf-Alexa 647 signal in nasal turbinate epithelia.
e) High power magniﬁcation (×400) of white box highlighted in (d) showing progress
of ﬂuorescent Tf through epithelia and accumulating within cells in stroma. f) Tf-Alexa
647 applied intravaginally in mice was visualized within sub-epithelial lamina propria
2 hours after application (arrows). Tf-Alexa 647 accumulated within cells enabling de-
tection, as diffuse Tf-Alexa 647 cannot be seen. g) After intravaginal administration of
Tf-Alexa 647 (red), signal was found to co-localize with a proportion of MHC Class II+
cells revealed by staining with a FITC labeled antibody (M5/114.15.2) (green) in the
sub-epithelial stroma (co-localization—yellow, examples shown with arrows). h)
After intravaginal administration of Tf-gp140 and staining with gp140-speciﬁc mAb
5F3 followed by a FITC labeled anti-Ig secondary, occasional cells with dendritic-like
morphology were detected with distinctive punctate staining.
246 J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249In this current study we set out to improve mucosal vaccination
without compromising the integrity of the mucosae and exposing
that surface to opportunistic pathogens. We used the transferrin re-
ceptor CD71 as an efﬁcient and natural transporter of its ligand, and
were able to demonstrate that a complex macromolecular “cargo”
vaccine antigen conjugated to the native transferrin molecule was
transported across an intact mucosal epithelium and deposited at
the basolateral surface. We selected the HIV gp140 glycoprotein asc
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tioour model cargo antigen, not because of any inherent ability to elicit
potent viral neutralizing antibodies but due to the large size of the tri-
meric protein conjugate. Successful delivery of such a molecule pro-
vides proof of concept for our method and the second or third
generation of a designed optimized vaccine antigen could easily re-
place our current model protein. Targeted transepithelial delivery
has previously been described for an insulin–transferrin conjugate
that was detected in rat serum 4 hours after oral administration [18].
Crucially, in the experiments described here, we demonstrated that
Tf-gp140, which formed high molecular weight complexes (data not
shown), retained high afﬁnity binding to CD71. In initial in vitro ex-
periments the transcytosis of Tf-gp140 conjugate, which was abrogat-
ed by competition with excess transferrin, occurred with linear
accumulation kinetics indicating that the transport was rate-limited
or controlled. Speciﬁc transport of the conjugate was evident even at
very low transferrin concentrations in the apical transwell chamber
but was inhibited in the presence of an inhibitor of intracellular trans-
port. These observations together with the demonstration of mainte-
nance of binding kinetics to CD71 indicate that the transport of the
transferrin conjugatewasmediated by the cognate CD71 receptor. No-
tably, the Tf-gp140 conjugation processmaintained the oligomeric na-
ture of the gp140 that is believed to be important for presentation of
the HIV envelope protein in a state that mimics that expressed on
the virion [27]. In vivo, appearance of human transferrin in murine
blood after application to the vaginal vault or nasal cavity, presumably
reﬂects the high identity between human and murine transferrin pro-
teins and is in agreement with high level expression of CD71 on pri-
mary cervico-vaginal epithelium shown here and in other published
data on a variety of mucosally associated epithelia including the
upper respiratory tract [28–32]. The ﬁnding that transcytosed trans-
ferrin conjugates localized to cells with dendritic morphology in the
underlying stroma is likely due to the expression of CD71 on these
cells. These observations suggest that the transferrin component of
the conjugate conferred a dual functionality to the conjugate complex
of an initial transcytosis of a cargo vaccine antigen across the mucosal
epithelial barrier followed by a speciﬁc targeting to sub-mucosal APCs.
Our immunogenicity experiments revealed that Tf-gp140, in con-
trast to gp140 alone, could be highly immunogenic when applied di-
rectly to a mucosal surface, eliciting equivalent responses to a
standard parenteral prime and mucosal boost regime. This has signif-
icant practical potential for vaccine administration as needle based
delivery systems have many associated risks, including needle stick
injuries and transfer of infections, costs for syringe disposal and the
requirement for administration by trained personnel, a particular
concern in resource poor settings. Despite demonstrating in vitro
and in vivo trafﬁcking of Tf-gp140 across the cervico-vaginal barrier,
strikingly, only nasal administration elicited signiﬁcant antibody re-
sponses. There could be a number of explanations for this ﬁnding.
The vaginal and nasal mucosae are anatomically different. The local
environment at the surface of nasal or vaginal mucosae could poten-
tially differ in terms of local secretion of proteases or the resident
ﬂora, but it is unlikely the ﬂora could effect such a dramatic result
in healthy pathogen free mice [15]. While we clearly observed punc-
tate staining distributed throughout the sub-epithelial lamina propriaFig. 5. Application of Tf-gp140 to the nasal mucosae elicits potent antigen-speciﬁc
serum antibody responses. Animals (n=8) were vaccinated via the nasal or vaginal
mucosal route three times at two-week intervals with or without a single prior subcu-
taneous prime. a) Serum IgG antibody geometric mean titres (GMT) assessed by ELISA
at week 1 ( □ ), 3 ( ) and 8 ( ■ ) following the initial mucosal application with either
gp140 or the Tf-gp140 conjugate. b) Serum IgG antibody GMTs assessed by ELISA after
a single subcutaneous prime with 10 μg unadjuvanted gp140 followed with three mu-
cosal boosts. Timepoints shown are at week 1 (□ ), 3 ( ) and 8 (■ ) following the mu-
cosal application with either gp140 or the Tf-gp140 conjugate. Values represent
end point dilution titres ± S.D. of the group (n=8) (***p=0.0002 **p=0.0019).
c) Serum IgG1/IgG2a ratios were assessed at week 8 using the GMT of each isotype.
Statistical analysis was carried out using a Mann Whitney rank-sum test with signiﬁ-
cance indicated by values pb0.05.
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247J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249of both tissues we noted that the nasal epithelia contained much
more ﬂuorescent Tf at all timepoints where we looked, though this
could be a result of the tissue processing and dissolution of mucus
that may trap, and possibly retain, a large proportion of the applied
material. Indeed, in vivo imaging of mice revealed that topical appli-
cation of Tf-Alexa into the vaginal vault maintained a strong ﬂuores-
cent signal for 24 hours post application (Fig. 3).
A more likely explanation is that the observed differences are due
to the immunologic potential of the respective mucosae. The
nasopharynx-associated lymphoid tissue (NALT) is immunologically
inductive as it contains numerous microfold cells (M cells) and high
densities of immune competent cells beneath the follicle-associated
epithelium (FAE) while no such follicles exist in the cervico-vaginal
epithelium [33–35]. While we observed equally intense CD71 expres-
sion on M cells and surrounding epithelium as on non-M cell associ-
ated mucosae it is likely that these specialized antigen-sampling
cells with their high concentration of immune reactive cells within
the follicles play an important role in elicitation of immunity. Within
the vagina, the major immune competent cells are dendritic cells and
macrophages with the DCs residing in both the submucosal epitheli-
um and in the overlying stratiﬁed epithelium and the macrophages
being largely restricted to sub-mucosal stroma [14]. DCs located in
the stratiﬁed epithelium, variously referred to as Langerhans cells
(LC), dermal dendritic cells (DDC) or vaginal epithelial dendritic
cells (VEDC), are uniquely positioned to capture foreign antigens or
pathogens that breach the epithelial barrier as well as perform
house-keeping functions such as clearance of apoptotic keratinocytes.
However, the ability of these vaginal LC, that are most similar to LC
resident in skin, to stimulate naïve T cells is debated and it is reported
that these APC populations are at least partly tolerogenic in nature
[12,14,36]. The signiﬁcant differences between the immune re-
sponses we observed after topical vaginal or nasal vaccination, even
in the context of a systemic priming inoculation, are therefore com-
patible with the presumed differential inductive potential of the
two different mucosae.
Our observation that only the Tf-gp140 conjugate was able to elicit
signiﬁcant immunity after a topical mucosal application while both
unconjugated gp140 or the conjugate were equally able to boost a
systemic priming vaccination strongly suggests that the quantity of
antigen that gets through the mucosal epithelium has a signiﬁcant
impact on the resulting immune response. Indeed the data suggest
that there may be a threshold where responses are initiated and am-
pliﬁed but below this threshold immune responses are weak or ab-
sent. A dose escalation study will determine if this is correct and
will also provide information on the dose-sparing capacity of the Tf-
gp140 conjugate. Unlike previous studies involving intranasal immu-
nization [37–42], no adjuvants were used in the present study. It
would now be interesting to determine if immunogenicity of the Tf-
gp140 conjugate would be enhanced by the use of low concentrations
of adjuvant that may be less likely to damage epithelial surfaces. The
strikingly enhanced skewing of the serum antibody response toward
Th2-type when mice were intranasally immunized with Tf-gp140 in-
dicated that the conjugate may alter antibody-secreting B cell devel-
opment and differentiation [43–45]. Moreover, the observed
increase in the relative proportion of IgA within the murine vaginalFig. 6. The Tf-gp140 conjugate signiﬁcantly augments antigen-speciﬁc mucosal IgA
production after application to the nasal mucosae. Antigen-speciﬁc mucosal IgG (a,
b) and IgA (c, d) titres were measured in mucosal lavage samples from murine vaginal
vaults 8 weeks following the initial mucosal application with either gp140 or the Tf-
gp140 conjugate. The panels show the reciprocal endpoint dilutions, normalized for
total Ig, of each individual mouse within a group. Open symbols (a, c) indicate that
the mice received only mucosal applications of the formulations while closed symbols
(b, d) indicate that the mice also received a subcutaneous injection with 10 μg unadju-
vanted gp140 two weeks before any mucosal applications (**p=0.0019). Statistical
analysis was carried out using a Mann Whitney rank-sum test with signiﬁcance indi-
cated by values pb0.05.
248 J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249vault after Tf-gp140 nasal vaccination suggests that efﬁcient mucosal
priming in the absence of exogenous adjuvant may profoundly inﬂu-
ence the quality of the local antibody response.
In conclusion, we have demonstrated that a natural endogenous
molecular transport system can be utilized to target a large complex
antigen, trimeric HIV gp140, to mucosal immune inductive tissue in
the absence of adjuvants. Moreover, delivery of antigen using this
novel needle-less modality induces a distinctive antibody proﬁle
that may be important in generating effective vaccine responses at
the portal of pathogen entry.
Disclosure
The authors declare no conﬂict of interest.
Acknowledgements
The authors would like to thank Prof. Hans Wolf, Prof. Ralf Wag-
ner, Dr. Simon Jeffs and Dr. Dietmar Katinger for the provision of plas-
mids and antigen. The study was integrated with efforts to
standardize HIV vaccine development through the EUROPRISE Net-
work of Excellence in Microbicides and Vaccines.
Appendix A. Supplementary data
Supplementary data to this article can be found online at doi:10.
1016/j.jconrel.2011.11.009.
References
[1] T.B. Clarke, N. Francella, A. Huegel, J.N. Weiser, Invasive bacterial pathogens ex-
ploit TLR-mediated downregulation of tight junction components to facilitate
translocation across the epithelium, Cell Host Microbe 9 (2011) 404–414.
[2] L. Gu, N. Li, J. Gong, Q. Li, W. Zhu, J. Li, Berberine ameliorates intestinal epithelial
tight-junction damage and down-regulates myosin light chain kinase pathways
in a mouse model of endotoxinemia, J. Infect. Dis. 203 (2011) 1602–1612.
[3] H.Y. Wu, M.W. Russell, Nasal lymphoid tissue, intranasal immunization, and com-
partmentalization of the common mucosal immune system, Immunol. Res. 16
(1997) 187–201.
[4] S. Dahan, F. Roth-Walter, P. Arnaboldi, S. Agarwal, L. Mayer, Epithelia: lympho-
cyte interactions in the gut, Immunol. Rev. 215 (2007) 243–253.
[5] J.M. Wells, O. Rossi, M. Meijerink, P. van Baarlen, Epithelial crosstalk at the
microbiota-mucosal interface, Proc. Natl. Acad. Sci. U. S. A. 108 (Suppl 1) (2011)
4607–4614.
[6] A.C. Soloff, S.M. Barratt-Boyes, Enemy at the gates: dendritic cells and immunity
to mucosal pathogens, Cell Res. 20 (2010) 872–885.
[7] X. Zhang, A.A. Chentouﬁ, G. Dasgupta, A.B. Nesburn, M. Wu, X. Zhu, D. Carpenter,
S.L. Wechsler, S. You, L. BenMohamed, A genital tract peptide epitope vaccine tar-
geting TLR-2 efﬁciently induces local and systemic CD8+ T cells and protects
against herpes simplex virus type 2 challenge, Mucosal Immunol. 2 (2009)
129–143.
[8] C. Luci, C. Hervouet, D. Rousseau, J. Holmgren, C. Czerkinsky, F. Anjuere, Dendritic
cell-mediated induction of mucosal cytotoxic responses following intravaginal
immunization with the nontoxic B subunit of cholera toxin, J. Immunol. 176
(2006) 2749–2757.
[9] G. Pialoux, H. Hocini, S. Perusat, B. Silberman, D. Salmon-Ceron, L. Slama, V. Journot,
E. Mathieu, C. Gaillard, K. Petitprez, O. Launay, G. Chene, Phase I study of a candidate
vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal
route to HIV-seronegative volunteers: the ANRS VAC14 study, Vaccine 26 (2008)
2657–2666.
[10] M.P. Cranage, C.A. Fraser, A. Cope, P.F. McKay, M.S. Seaman, T. Cole, A.N.Mahmoud, J.
Hall, E. Giles, G. Voss, M. Page, N. Almond, R.J. Shattock, Antibody responses after
intravaginal immunisation with trimeric HIV-1(CN54) clade C gp140 in Carbopol
gel are augmented by systemic priming or boostingwith an adjuvanted formulation,
Vaccine (2011).
[11] R.J. Shattock, J.P. Moore, Inhibiting sexual transmission of HIV-1 infection, Nat.
Rev. Microbiol. 1 (2003) 25–34.
[12] C.A. Black, L.C. Rohan, M. Cost, S.C. Watkins, R. Draviam, S. Alber, R.P. Edwards,
Vaginal mucosa serves as an inductive site for tolerance, J. Immunol. 165
(2000) 5077–5083.
[13] J.K. Sherwood, L. Zeitlin, X. Chen, K.J. Whaley, R.A. Cone, W.M. Saltzman, Resi-
dence half-life of IgG administered topically to the mouse vagina, Biol. Reprod.
54 (1996) 264–269.
[14] N. Iijima, J.M. Thompson, A. Iwasaki, Dendritic cells and macrophages in the gen-
itourinary tract, Mucosal Immunol. 1 (2008) 451–459.
[15] R.A. Cone, Barrier properties of mucus, Adv. Drug Deliv. Rev. 61 (2009) 75–85.[16] M.J. McElrath, S.C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O.D.
Defawe, D.K. Carter, J. Hural, R. Akondy, S.P. Buchbinder, M.N. Robertson, D.V.
Mehrotra, S.G. Self, L. Corey, J.W. Shiver, D.R. Casimiro, HIV-1 vaccine-induced im-
munity in the test-of-concept Step Study: a case-cohort analysis, Lancet 372
(2008) 1894–1905.
[17] Z.M. Qian, H. Li, H. Sun, K. Ho, Targeted drug delivery via the transferrin receptor-
mediated endocytosis pathway, Pharmacol. Rev. 54 (2002) 561–587.
[18] C.Q. Xia, J. Wang, W.C. Shen, Hypoglycemic effect of insulin–transferrin conjugate
in streptozotocin-induced diabetic rats, J. Pharmacol. Exp. Ther. 295 (2000)
594–600.
[19] C.M. Rodenburg, Y. Li, S.A. Trask, Y. Chen, J. Decker, D.L. Robertson, M.L. Kalish,
G.M. Shaw, S. Allen, B.H. Hahn, F. Gao, Near full-length clones and reference se-
quences for subtype C isolates of HIV type 1 from three different continents,
AIDS Res. Hum. Retroviruses 17 (2001) 161–168.
[20] L. Su, M. Graf, Y. Zhang, H. von Briesen, H. Xing, J. Kostler, H. Melzl, H. Wolf, Y.
Shao, R. Wagner, Characterization of a virtually full-length human immunodeﬁ-
ciency virus type 1 genome of a prevalent intersubtype (C/B') recombinant strain
in China, J. Virol. 74 (2000) 11367–11376.
[21] M.P. Cranage, C.A. Fraser, Z. Stevens, J. Huting, M. Chang, S.A. Jeffs, M.S. Seaman, A.
Cope, T. Cole, R.J. Shattock, Repeated vaginal administration of trimeric HIV-1
clade C gp140 induces serum and mucosal antibody responses, Mucosal Immu-
nol. 3 (2010) 57–68.
[22] G. Krashias, A.K. Simon, F. Wegmann, W.L. Kok, L.P. Ho, D. Stevens, J. Skehel, J.L.
Heeney, A.E. Moghaddam, Q.J. Sattentau, Potent adaptive immune responses in-
duced against HIV-1 gp140 and inﬂuenza virus HA by a polyanionic carbomer,
Vaccine 28 (2010) 2482–2489.
[23] A.G. Camacho, L.H. Teixeira, D.Y. Bargieri, S.B. Boscardin, S. Soares Ida, R.S.
Nussenzweig, V. Nussenzweig, M.M. Rodrigues, TLR5-dependent immunoge-
nicity of a recombinant fusion protein containing an immunodominant epitope of
malarial circumsporozoite protein and the FliC ﬂagellin of Salmonella Typhimurium,
Mem. Inst. Oswaldo Cruz 106 (Suppl 1) (2011) 167–171.
[24] A. Iwasaki, R. Medzhitov, Regulation of adaptive immunity by the innate immune
system, Science 327 (2010) 291–295.
[25] R.B. Couch, Nasal vaccination, Escherichia coli enterotoxin, and Bell's palsy, N.
Engl. J. Med. 350 (2004) 860–861.
[26] M. Mutsch, W. Zhou, P. Rhodes, M. Bopp, R.T. Chen, T. Linder, C. Spyr, R. Steffen,
Use of the inactivated intranasal inﬂuenza vaccine and the risk of Bell's palsy in
Switzerland, N. Engl. J. Med. 350 (2004) 896–903.
[27] D.R. Burton, R.C. Desrosiers, R.W. Doms, W.C. Koff, P.D. Kwong, J.P. Moore, G.J.
Nabel, J. Sodroski, I.A. Wilson, R.T. Wyatt, HIV vaccine design and the neutralizing
antibody problem, Nat. Immunol. 5 (2004) 233–236.
[28] E.A. Heilig, K.J. Thompson, R.M. Molina, A.R. Ivanov, J.D. Brain, M. Wessling-
Resnick, Manganese and iron transport across pulmonary epithelium, Am. J. Phy-
siol. Lung Cell. Mol. Physiol. 290 (2006) L1247–L1259.
[29] E.H. Morgan, P.S. Oates, Mechanisms and regulation of intestinal iron absorption,
Blood Cells Mol. Dis. 29 (2002) 384–399.
[30] P.S. Oates, E.H. Morgan, Effects of dietary iron loading with carbonyl iron and of
iron depletion on intestinal growth, morphology, and expression of transferrin
receptor in the rat, Anat. Rec. 246 (1996) 364–371.
[31] A. Widera, K.J. Kim, E.D. Crandall, W.C. Shen, Transcytosis of GCSF-transferrin
across rat alveolar epithelial cell monolayers, Pharm. Res. 20 (2003) 1231–1238.
[32] Z.B. Zhu, S.K. Makhija, B. Lu, M. Wang, A.A. Rivera, M. Preuss, F. Zhou, G.P. Siegal,
R.D. Alvarez, D.T. Curiel, Transport across a polarized monolayer of Caco-2 cells by
transferrin receptor-mediated adenovirus transcytosis, Virology 325 (2004)
116–128.
[33] E.L. Johansson, C. Rask, M. Fredriksson, K. Eriksson, C. Czerkinsky, J. Holmgren,
Antibodies and antibody-secreting cells in the female genital tract after vaginal
or intranasal immunization with cholera toxin B subunit or conjugates, Infect.
Immun. 66 (1998) 514–520.
[34] J. Mestecky, M.W. Russell, Induction of mucosal immune responses in the human
genital tract, FEMS Immunol. Med. Microbiol. 27 (2000) 351–355.
[35] M. Vajdy, M. Singh, J. Kazzaz, E. Soenawan, M. Ugozzoli, F. Zhou, I. Srivastava, Q.
Bin, S. Barnett, J. Donnelly, P. Luciw, L. Adamson, D. Monteﬁori, D.T. O'Hagan, Mu-
cosal and systemic anti-HIV responses in rhesus macaques following combina-
tions of intranasal and parenteral immunizations, AIDS Res. Hum. Retroviruses
20 (2004) 1269–1281.
[36] M.B. Lutz, A. Dohler, H. Azukizawa, Revisiting the tolerogenicity of epidermal Lan-
gerhans cells, Immunol. Cell Biol. 88 (2010) 381–386.
[37] A.D. Cristillo, M.G. Ferrari, L. Hudacik, B. Lewis, L. Galmin, B. Bowen, D. Thompson,
N. Petrovsky, P. Markham, R. Pal, Induction of mucosal and systemic antibody and
T-cell responses following prime-boost immunization with novel adjuvanted
human immunodeﬁciency virus-1-vaccine formulations, J. Gen. Virol. 92 (2011)
128–140.
[38] W.M. Gwinn, S.M. Kirwan, S.H. Wang, K.A. Ashcraft, N.L. Sparks, C.R. Doil, T.G.
Tlusty, L.S. Casey, S.K. Hollingshead, D.E. Briles, R.S. Dondero, A.J. Hickey, W.M.
Foster, H.F. Staats, Effective induction of protective systemic immunity with
nasally administered vaccines adjuvanted with IL-1, Vaccine 28 (2010)
6901–6914.
[39] H. Kayamuro, Y. Yoshioka, Y. Abe, S. Arita, K. Katayama, T. Nomura, T. Yoshikawa,
R. Kubota-Koketsu, K. Ikuta, S. Okamoto, Y. Mori, J. Kunisawa, H. Kiyono, N. Itoh, K.
Nagano, H. Kamada, Y. Tsutsumi, S. Tsunoda, Interleukin-1 family cytokines as
mucosal vaccine adjuvants for induction of protective immunity against inﬂuenza
virus, J. Virol. 84 (2010) 12703–12712.
[40] P. Petersson,M. Hedenskog, D. Alves,M. Brytting, U. Schroder, A. Linde, A. Lundkvist,
The Eurocine L3 adjuvants with subunit inﬂuenza antigens induce protective immu-
nity in mice after intranasal vaccination, Vaccine 28 (2010) 6491–6497.
249J.F.S. Mann et al. / Journal of Controlled Release 158 (2012) 240–249[41] J. Xu, W. Dai, Z. Wang, B. Chen, Z. Li, X. Fan, Intranasal vaccination with chitosan-
DNA nanoparticles expressing pneumococcal surface antigen a protects mice
against nasopharyngeal colonization by Streptococcus pneumoniae, Clin. Vaccine
Immunol. 18 (2011) 75–81.
[42] H. Yamanaka, T. Hoyt, X. Yang, S. Golden, C.M. Bosio, K. Crist, T. Becker,M.Maddaloni,
D.W. Pascual, A nasal interleukin-12 DNA vaccine coexpressing Yersinia pestis F1-V
fusion protein confers protection against pneumonic plague, Infect. Immun. 76
(2008) 4564–4573.[43] Q.A. Hamid, L.A. Cameron, Recruitment of T cells to the lung in response to anti-
gen challenge, J. Allergy Clin. Immunol. 106 (2000) S227–S234.
[44] R.I. Nurieva, Y. Chung, Understanding the development and function of T follicu-
lar helper cells, Cell. Mol. Immunol. 7 (2010) 190–197.
[45] K.M. Smith, L. Pottage, E.R. Thomas, A.J. Leishman, T.N. Doig, D. Xu, F.Y. Liew, P.
Garside, Th1 and Th2 CD4+ T cells provide help for B cell clonal expansion and
antibody synthesis in a similar manner in vivo, J. Immunol. 165 (2000)
3136–3144.
